Chong Kun Dang Holdings Corp. Overview
The listing has not moved and the company has not changed its name since 2013.
Identification Table
| Item | Detail |
|---|---|
| Legal name | Chong Kun Dang Holdings Corp. (㈜종근당홀딩스) |
| Former name | Chong Kun Dang Corp. (㈜종근당). The listed entity became the holding company and was renamed when the operating business was split off in November 2013. |
| Founding | 7 May 1941 (Gungbon Pharmacy, the predecessor business), per company website |
| Incorporation | Registered as a stock company in January 1956. Incorporated in the Republic of Korea. |
| Headquarters | 8 Chungjeong-ro, Seodaemun-gu, Seoul (Chong Kun Dang Building). Tel. +82-2-6373-0600 |
| Exchange / ticker | Korea Exchange, KOSPI: 001630 |
| ISIN | KR7001630000 (standard KRX format for code 001630; confirm against the KRX register before use) |
| CUSIP | Not applicable (no US listing) |
| Fiscal year end | 31 December (FY2025 was the company's 71st fiscal period) |
| Share capital | KRW 12,525 million at par value KRW 2,500. This implies about 5.01 million issued shares; about 4.76 million shares are outstanding excluding treasury stock. |
| Employees (holding company, standalone) | 37 (S&P Global, latest); 35 (June 2026, TheVC). |
| Employees (group context) | Chong Kun Dang (associate): about 2,346 (2025). Kyongbo Pharm: 575 (March 2026). CKD Healthcare: about 330. |
| Auditor | — |
| Market capitalisation | About KRW 178–183 bn (KRW 37,350 at 6 October 2026 on 4.76m outstanding shares, S&P Global; KRW 182.9 bn on issued-share basis, Butler) |
| CEO | Choi Hee-nam, Representative Director (since 28 March 2024) |
| Chairman / controlling shareholder | Lee Jang-han (33.73% direct stake) |
| Website | www.ckd-holdings.com |
CKD Holdings is the pure holding company at the apex of the Chong Kun Dang Group, one of South Korea's oldest pharmaceutical groups. The listed entity reports consolidated revenue of about KRW 959 bn (FY2025). Almost all of it comes from three healthcare subsidiaries:
CKD Healthcare: (51%-owned, unlisted): consumer health functional foods. Its Lacto-Fit probiotic franchise made it the group's largest consolidated revenue line.
Kyongbo Pharm: (43.41%, KOSPI): synthetic APIs and finished generics, now pivoting into antibody-drug conjugate (ADC) contract manufacturing.
CKD Bio: (about 39%, KOSPI): fermentation APIs, probiotics and botulinum toxin.
The group's flagship prescription-drug company, Chong Kun Dang Pharmaceutical (26.70%, KOSPI: 185750; FY2025 revenue KRW 1.69 tn), is equity-accounted rather than consolidated. A large share of the holding company's intrinsic value therefore sits outside its reported revenue line.
The shares trade at a deep holding-company discount: about 0.2–0.3x book value and a price-to-earnings ratio of about 3–4x. Owner-family succession is actively under way, and this shapes capital allocation.
What the Company Does
CKD Holdings is a pure holding company (순수지주회사) under Korea's Monopoly Regulation and Fair Trade Act. Its own business activities are:
-
Owning and managing equity stakes in group companies.
-
Collecting brand royalties, dividends, rental and service fees.
-
Allocating capital, including stake purchases in subsidiaries and new investments.
In March 2024 it added investment-related business purposes to its articles of incorporation. These cover investing in new-technology businesses, start-ups and SMEs, establishing new-technology finance subsidiaries, and accelerator activities. The change signals an intent to act as an investor, not only a passive parent (Dailypharm, 29 February 2024).
Company's Own Description
| Category | Affiliates |
|---|---|
| Healthcare | Chong Kun Dang, CKD Bio, Kyongbo Pharm, CKD Healthcare |
| Real-estate leasing | CKD Industry |
| Construction / environment | Bell E&C |
| Services / transport | Bell SM (a family-owned affiliate, not a holding-company subsidiary) |
| Marketing solutions | Bell Communications |
| IT | Bell I&S |
On its corporate website the company presents itself as follows:
-
It was launched in November 2013 when Chong Kun Dang converted to a holding-company structure to pursue a new leap as a global pharmaceutical group.
-
Its role is to maximise the value of operating companies, led by Chong Kun Dang, by concentrating on new business development and new investment.
-
It aims to find future growth engines and build a sustainable management system.
The website lists its business line as "holding business and management consulting." It groups affiliates into six categories:
Digital Daily (media) was added in 2025.
Independent Characterisation
Economically, CKD Holdings is best understood as three businesses plus an equity stake.
-
A consumer-health company (CKD Healthcare). It carries the consolidated income statement. It generated about 41% of consolidated revenue in Q2 2026. Profitability swings with marketing intensity in a saturated, promotion-heavy Korean supplements market.
-
A B2B active-ingredient manufacturer (Kyongbo Pharm and CKD Bio). Together these generated about 43% of Q2 2026 revenue. They sell synthetic and fermentation APIs to domestic and international drugmakers, including the group's own Chong Kun Dang. Both are adding higher-value platforms: ADC CDMO at Kyongbo and botulinum toxin at CKD Bio.
-
Group services and property. CKD Industry's real-estate leasing plus advertising, IT, construction and media affiliates generated about 14% of revenue. Holding-company royalty and fee income added about 2%.
-
A 26.70% equity stake in Chong Kun Dang Pharmaceutical. Chong Kun Dang is a top-tier Korean prescription-drug marketer and developer. It is accounted for by the equity method, so it appears as share of profit and long-term investments rather than revenue. Equity-method gains were about KRW 21.6 bn in FY2025 and KRW 21.8 bn in FY2024 (S&P Global cash-flow data).
Revenue Model Mix
| Revenue type | Main source | Approximate weight (Q2 2026, % of consolidated revenue) |
|---|---|---|
| Product sales – consumer (health functional foods, cosmetics) | CKD Healthcare | ~41% |
| Product sales – B2B APIs and finished generics | Kyongbo Pharm | ~28% |
| Product sales – fermentation APIs, probiotics, toxin | CKD Bio | ~15% |
| Services / leasing / advertising / IT / media | CKD Industry and others | ~14% |
| Brand royalty, fees, rent, dividends (holding-company level) | CKD Holdings standalone | ~2% |
Source: Butler segment split (Q2 2026). Subscription or licensing revenue at consolidated level is negligible. Milestone and licence income such as the Novartis CKD-510 milestones accrues at Chong Kun Dang, the equity-accounted associate.
Value-Chain Position, Customers and End-Markets
| Business | Value-chain position | Main customers / channels | End-markets |
|---|---|---|---|
| CKD Healthcare | Branded consumer products, with own plant at Dangjin | Home shopping (29.8% of supplement sales in 2023, down from 42.2% in 2021), online, own mall, retail (including a past Daiso entry), agency network | Korean consumer health and wellness |
| Kyongbo Pharm | Upstream API synthesis plus finished-dose generics; ADC CDMO under construction | Domestic pharma (including Chong Kun Dang), export API customers, hospitals and pharmacies for finished products | Antibiotics (cephalosporins), cardiovascular (atorvastatin), analgesics; ADC developers |
| CKD Bio | Upstream fermentation API; probiotic raw materials and contract manufacturing; aesthetic toxin | Global and domestic drugmakers; health-food brands; aesthetic clinics | Transplant immunosuppression, anti-infectives, probiotics, aesthetics |
| CKD Industry and others | Real-estate leasing, group services | Group companies and third parties | Property, advertising, IT, media |
Strategy
Stated Strategy Themes
These are paraphrased from company disclosures and the AGM.
-
Maximise operating-company value through new business development and new investment. The holding company frames its role as finding growth engines and building a sustainable management system (corporate website).
-
Responsible management and objective performance evaluation of subsidiaries. The aim is fast, specialised decision-making by business line, group synergy, and higher corporate and shareholder value (company statement on the June 2026 bond).
-
Strengthen control of subsidiaries. Stake purchases are explicitly tied to raising dividend income and brand-royalty revenue (company statement, June 2026).
-
ESG integration. Targets 2050 carbon neutrality, supply-chain ESG management and fair-trade compliance, under eight material issues (Sustainability Report 2022/2023).
Initiatives in the Last 24 Months
| Initiative | Entity | Date | Detail / target |
|---|---|---|---|
| Investment-holding capability | CKD Holdings | March 2024 onward | New investment business purposes; M&A-experienced director appointed |
| Digital, AI and media diversification | CKD Holdings | November 2024; August 2025 | D-Tribe acquisition; Digital Daily (KRW 20 bn) to build digital and AI insight for pharma |
| Subsidiary stake build-up | CKD Holdings | 2023–2028 | About KRW 10 bn a year of stake purchases planned through 2028; KRW 30 bn earmarked from the June 2026 bond |
| Debt refinancing and term-out | CKD Holdings | June 2026 | KRW 77 bn bond: KRW 32 bn 2-year and KRW 45 bn 3-year. First dual-tranche issue. |
| ADC CDMO build-out | Kyongbo Pharm | 2024–2027 | Asan ADC GMP plant (KRW 96 bn). Target of KRW 1 tn ADC CDMO revenue by 2033. Government projects: KRW 16.9 bn MOTIE ADC project (2025) and AI autonomous-lab project (KRW 2.4 bn grant to Kyongbo within KRW 19.2 bn total, to December 2029). |
| Toxin commercialisation and globalisation | CKD Bio | 2025–2027 | Korean launch (July 2025); China filing after Phase 3; US Phase 1; halal positioning |
| Profit-first restructuring | CKD Healthcare | 2025–2026 | Marketing efficiency and own-mall focus. FY2025 operating income KRW 32.3 bn; H1 2026 margin 9.8%. |
| Large-scale bio R&D campus | Chong Kun Dang (associate) | 2025–2033 | Baegot complex (KRW 2.2 tn total); KRW 1 tn Woori Bank financing agreement (May 2026); KRW 61.1 bn exchangeable bond (September 2025); public bonds |
| NRDO and R&D reorganisation | Chong Kun Dang (associate) | October 2025; mid-2026 | Archela (CKD-508, CKD-514, CKD-513); Neurateon (formulation and technology research subsidiary); CKD USA |
| Obesity and blockbuster co-promotion | Chong Kun Dang (associate) | October 2025 onward | Wegovy co-promotion (about KRW 48.8 bn in Q1 2026 per analyst estimate); Evenity; Eylea |
Medium-Term Financial Targets and Guidance
| Entity | Target |
|---|---|
| Kyongbo | KRW 1 tn ADC CDMO revenue by 2033 |
| CKD Healthcare | Double-digit operating margin by 2027 |
CKD Holdings does not publish consolidated financial guidance. Subsidiary-level targets are:
Chong Kun Dang's CEO guided qualitatively at the March 2026 AGM: timely new launches, product competitiveness and market responsiveness to deliver solid profit growth.
Products & Services
CKD Healthcare (Health Functional Foods, Foods, Cosmetics)
| Product / brand | Description | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Lacto-Fit (락토핏) Saengyusangyun | Powder-stick probiotic line in age- and gender-specific variants (Gold, Core, Kids, Bebe, Beauty). Korea's market-leading probiotic by share. Accounted for nearly 60% of company sales at Q4 2019. | Mass market, all ages | 2016 launch; continuous line extensions | Consumer retail (not disclosed) |
| Drinkable Lacto-Fit (Original, Apple) | Probiotic yoghurt drinks | Convenience-oriented consumers | Launched 2024 | Retail |
| Aikeo (아이커) | Children's growth / height-support supplement | Parents of children | Award-winning product since 2016 | Retail |
| Promega (프로메가) | Omega-3 (EPA/DHA) range | Adults, cardiovascular health | Ongoing | Retail |
| Im-Vita (아임비타) | Multivitamin range | Adults | Ongoing | Retail |
| Dr.Care Dang Coach Zero | Nutritional formula for diabetic patients | Diabetic consumers | 2,024 | Retail |
| GL-Fit Diet; Diet Coach | Body-fat-reduction probiotic; weight-control formula | Weight-management consumers | 2,024 | Retail |
| Berberine product | Blood-glucose-management supplement | Metabolic-health consumers | Launched 2025–2026 (Dailypharm) | Retail |
| Red ginseng and other health foods | Part of a stated 100+ SKU range | Gifting and seniors | Ongoing | Retail |
| Bellasu; Contramark Cream | Cosmetics brands | Beauty consumers | November 2017 | Retail |
Stated medium-term goal ("Beyond Healthcare 1-2-3" by 2027):
-
Become Korea's number-one health functional food company.
-
Achieve a double-digit operating margin.
-
Lead in three domains: supplements, cosmetics and food.
Kyongbo Pharm (APIs, Finished Dose, ADC CDMO)
| Product / service | Description | Customer | Status |
|---|---|---|---|
| Cephalosporin APIs (e.g., ceftizoxime, ceftriaxone) | Synthetic antibiotic APIs | Domestic and export drugmakers | Core legacy line |
| Atorvastatin API | Cardiovascular API | Domestic and export drugmakers | Core legacy line |
| Maxigesic (맥시제식) | Combination analgesic (finished product) | Hospitals and pharmacies | Recent launch; main growth driver of finished-dose sales |
| Finished generics (e.g., Eldocorp capsule, Janustin tablet, Dapacan tablet) | 23 products under licence-revocation litigation, about KRW 13.5 bn annual sales (5.1–5.65% of revenue) | Hospitals and pharmacies | At risk after the August 2026 first-instance loss; appeal and stay applications planned |
| ADC CDMO (Asan ADC GMP plant) | Covers preclinical, clinical and commercial supply of ADC drug substance and drug product. In-house linker and payload development. | Biotech and pharma ADC developers (MOUs with Binex, Protium Science, Pharosgen) | Plant under construction; investment KRW 96 bn; target of KRW 1 tn revenue by 2033 (company statement, June 2025) |
CKD Bio (Fermentation APIs, Probiotics, Toxin)
| Product / service | Description | Customer | Status |
|---|---|---|---|
| Immunosuppressant APIs | Fermentation-derived transplant immunosuppressants | Global and domestic drugmakers | Core. The API segment is 84% of CKD Bio revenue (Q2 2026). |
| Antibiotic APIs | Fermentation-derived anti-infectives | Global and domestic drugmakers | Core |
| Probiotics (raw material and finished CDMO) | Strain supply and contract manufacturing. Formerly the Lacto-Fit OEM until CKD Healthcare in-sourced production in 2022. | Health-food brands | 14% of revenue (Q2 2026) |
| Tyemvers 100U / 200U (티엠버스) | Botulinum toxin type A for moderate-to-severe glabellar lines. Uses a licensed European strain registered on GenBank. Fully animal-free and HSA-free process. First toxin with Indonesian BPJPH halal certification (per company/press). | Aesthetic clinics; Middle East and Southeast Asia targeted | 100U approved 31 March 2025; 200U approved 16 September 2025; domestic launch July 2025. China Phase 3 met non-inferiority versus Botox (74.0% vs 74.9% responders, January 2026); China filing planned. US IND cleared April 2025. |
| Microbiome CDMO | Contract services | Biotech | Development stage |
Other Consolidated Businesses
| Business | Offering |
|---|---|
| CKD Industry | Real-estate leasing |
| Bell Communications | TV and campaign advertising; handles major CKD Healthcare brands |
| D-Tribe | Digital and social-media marketing agency, founded 2001. Revenue KRW 0.41 bn post-acquisition, with an operating loss of KRW 0.27 bn. |
| Bell E&C | Construction and environment services |
| Bell I&S | IT services |
| Digital Daily | Online IT/business news and database information. A Naver content partner. Equity of KRW 9.5 bn at end-2024. |
| CKD Holdings (standalone) | Brand royalty, management fees, rental income |
Associate: Chong Kun Dang Pharmaceutical (Equity-Accounted)
| Category | Products |
|---|---|
| In-licensed / co-promoted blockbusters | Prolia and Evenity (Amgen, osteoporosis); Wegovy (Novo Nordisk, co-promotion from 1 October 2025); Prevenar (pneumococcal vaccine); Eylea (ophthalmology, recently launched); Godex (Celltrion Pharm); Fexuclu (Daewoong); Januvia (MSD). Atozet and Vytorin co-promotion with Organon has ended and Organon now sells them alone. |
| Own brands | Dilatrend (hypertension); Gliatilin (cognitive); Telmi series (over KRW 50 bn in H1 2026); Benfobel-S (vitamin); Penzal (OTC analgesic); Lucenbiess (ranibizumab biosimilar); Neulapeg (neutropenia); Gitec (natural-product gastritis drug, in price negotiation) |
| Asset | Mechanism / indication | Status |
|---|---|---|
| CKD-510 | HDAC6 inhibitor | Licensed to Novartis as PKN605; global Phase 2 with completion expected in 2027; first post-deal milestone received |
| CKD-702 | EGFR × c-Met bispecific, NSCLC | Phase 1 part 2 |
| CKD-703 | c-Met ADC | US Phase 1; first patient dosed |
| CKD-339 | Hypertension | MFDS Phase 3 IND, July 2026 |
| CKD-508 | CETP inhibitor | Transferred to Archela |
| CKD-514 | Oral GLP-1 | Transferred to Archela |
| CKD-513 | BBB-penetrant HDAC6 inhibitor | Transferred to Archela |
| CKD-704 / CKD-706 | Biosimilars (dermatology / autoimmune) | Development; CKD-706 EU Phase 1 planned |
This is not consolidated revenue, but it is central to valuation.
Financial Detail
Peer Comparison
| Company | Listing | CKD Holdings stake | Accounting | Main business |
|---|---|---|---|---|
Chong Kun Dang Pharmaceutical | KOSPI 185750 | 26.70% (largest shareholder; owner group total 40.15%) | Equity method (associate) | Ethical drugs, OTC, R&D |
CKD Healthcare (종근당건강) | Unlisted | 51.0% | Consolidated | Health functional foods, cosmetics |
Kyongbo Pharm (경보제약) | KOSPI 214390 | 43.41% (owner group total 60.55%) | Consolidated | Synthetic APIs, finished generics, ADC CDMO |
CKD Bio (종근당바이오) | KOSPI 063160 | About 39% (39.11% at March 2024) | Consolidated | Fermentation APIs, probiotics, botulinum toxin |
CKD Industry (종근당산업) | Unlisted | — | Consolidated | Real-estate leasing |
Bell Communications, Bell E&C, Bell I&S, D-Tribe | Unlisted | — | Consolidated (where controlled) | Advertising, construction/environment, IT, digital ads |
Digital Daily | Unlisted | 87.7% | Consolidated (from August 2025) | Online IT/business media |
Bell SM | Unlisted | None (owned 40% by Lee Ju-won, 30% by Lee Jang-han, 15% each by two daughters) | Not consolidated (family affiliate) | Services and transport; holds a small CKD Holdings stake |
Stake in Chong Kun Dang by Year
| Year | Stake in Chong Kun Dang |
|---|---|
| 2019 | 20.2% |
| 2022 | 25.1% |
| 2026 | 26.70% |
Segment Overview
| Segment | Q2 2026 share of revenue |
|---|---|
CKD Healthcare | 41% |
Kyongbo Pharm | 28% |
CKD Bio | 15% |
CKD Industry & others | 14% |
Holding company | 2% |
Segment revenue (KRW Bn)
| Segment revenue (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
CKD Healthcare revenue (KRW Bn) | 458.1 | 497.3 | 472.4 |
Kyongbo Pharm revenue (KRW Bn) | 216.4 | 238.6 | 264.1 |
CKD Bio revenue (KRW Bn) | 160.4 | 171.8 | 160.1 |
CKD Holdings consolidated revenue (KRW Bn) | 879.8 | 957.8 | 959.0 |
Segment operating income (KRW Bn)
| Segment operating income (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
CKD Healthcare operating income (KRW Bn) | 19.0 | -0.2 | 32.3 |
Kyongbo Pharm operating income (KRW Bn) | 5.6 | 10.5 | 3.5 |
CKD Bio operating income (KRW Bn) | -20.2 | 11.0 | 3.6 |
CKD Holdings consolidated operating income (KRW Bn) | 17.0 | 35.5 | 58.3 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
CKD Healthcare operating margin (%) | 4.1 | 0.0 | 6.8 |
Kyongbo Pharm operating margin (%) | 2.6 | 4.4 | 1.3 |
CKD Bio operating margin (%) | -12.6 | 6.4 | 2.2 |
CKD Healthcare revenue growth YoY (%) | -12.5 | 8.6 | -5.0 |
Kyongbo Pharm revenue growth YoY (%) | 3.7 | 10.3 | 10.7 |
CKD Bio revenue growth YoY (%) | 2.8 | 7.1 | -6.8 |
CKD Healthcare share of consolidated revenue, pre-elimination (%) | 52.1 | 51.9 | 49.3 |
Kyongbo Pharm share of consolidated revenue, pre-elimination (%) | 24.6 | 24.9 | 27.5 |
CKD Bio share of consolidated revenue, pre-elimination (%) | 18.2 | 17.9 | 16.7 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 926.0 | 909.0 | 879.8 | 957.8 | 959.0 |
Revenue growth YoY (%) | 7.9 | -1.8 | -3.2 | 8.9 | 0.1 |
Gross profit (KRW Bn) | 441.4 | 399.2 | 383.9 | 444.6 | 427.3 |
Operating income, company-reported (KRW Bn) | 34.4 | -32.9 | 17.0 | 35.5 | 58.3 |
D&A (KRW Bn) | 35.7 | 42.9 | 45.3 | 43.3 | 44.0 |
EBITDA, computed (KRW Bn) | 70.1 | 10.0 | 62.3 | 78.8 | 102.3 |
Net income incl. minorities (KRW Bn) | 25.8 | -22.7 | 40.6 | 40.3 | 54.3 |
Net income attributable to owners (KRW Bn) | 16.0 | 1.1 | 47.0 | 33.6 | 40.4 |
EPS basic, attributable (KRW) | 3,212 | 219 | 9,744 | 7,059 | 8,493 |
EPS diluted (KRW) | 3,212 | 219 | 9,744 | 7,059 | 8,493 |
Dividend per share (KRW) | — | — | 1,400 | — | 1,400 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin (%)
| Margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 47.7 | 43.9 | 43.6 | 46.4 | 44.6 |
Operating margin (%) | 3.7 | -3.6 | 1.9 | 3.7 | 6.1 |
EBITDA margin (%) | 7.6 | 1.1 | 7.1 | 8.2 | 10.7 |
Net margin, total net income (%) | 2.8 | -2.5 | 4.6 | 4.2 | 5.7 |
Net margin, attributable (%) | 1.7 | 0.1 | 5.3 | 3.5 | 4.2 |
Balance Sheet and Per-Share Data
| Balance-sheet item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 1,367.6 | 1,376.4 | 1,456.0 | 1,495.8 | 1,628.8 |
Cash & equivalents (KRW Bn) | 79.9 | 35.9 | 45.2 | 29.4 | 80.3 |
Cash & short-term investments (KRW Bn) | 144.9 | 82.8 | 81.2 | 61.1 | 117.1 |
Short-term debt incl. current portion of LTD (KRW Bn) | 179.0 | 285.6 | 390.3 | 369.5 | 480.3 |
Long-term debt (KRW Bn) | 163.0 | 141.3 | 72.1 | 107.4 | 55.8 |
Total debt incl. leases (KRW Bn) | 345.3 | 429.3 | 468.0 | 479.7 | 540.8 |
Net debt (KRW Bn) | 200.4 | 346.5 | 386.9 | 418.5 | 423.7 |
Total equity incl. minorities (KRW Bn) | 840.0 | 798.5 | 823.5 | 849.8 | 913.1 |
Equity attributable to owners (KRW Bn) | 541.0 | 528.9 | 563.0 | 587.5 | 637.0 |
Minority interest (KRW Bn) | 299.0 | 269.7 | 260.5 | 262.3 | 276.0 |
Goodwill & intangibles (KRW Bn) | 25.5 | 29.4 | 27.3 | 31.4 | 43.9 |
Long-term investments incl. Chong Kun Dang stake (KRW Bn) | 306.9 | 337.3 | 379.0 | 393.5 | 423.5 |
Inventory (KRW Bn) | 175.9 | 188.5 | 194.8 | 237.7 | 224.2 |
Working capital (KRW Bn) | 119.2 | -0.8 | -100.2 | -63.6 | -116.7 |
Book value per share (KRW) | 109,358 | 108,745 | 118,253 | 123,410 | 133,813 |
Cash-flow item
| Cash-flow item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | 40.5 | -46.5 | 37.1 | 24.0 | 76.0 |
Capital expenditure (KRW Bn) | 100.5 | 58.0 | 25.5 | 41.5 | 56.0 |
Free cash flow (KRW Bn) | -60.0 | -104.5 | 11.6 | -17.6 | 20.1 |
Cash acquisitions (KRW Bn) | 0.0 | 0.0 | 8.6 | -0.1 | 18.3 |
Dividends paid, incl. to minorities (KRW Bn) | 10.9 | 10.4 | 10.0 | 13.0 | 10.4 |
Share buybacks (KRW Bn) | 4.3 | 5.1 | 5.3 | 0.0 | 0.0 |
Net debt issued (KRW Bn) | 124.2 | 81.4 | 11.3 | 9.2 | 58.8 |
Cash interest paid (KRW Bn) | 5.3 | 10.2 | 19.4 | 20.7 | 20.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 3.07 | -2.77 | 5.00 | 4.82 | 6.16 |
ROA (%) | 1.64 | -1.50 | 0.75 | 1.50 | 2.31 |
ROIC (%) | 3.20 | -3.01 | 1.34 | 2.85 | 3.69 |
Current ratio (x) | 1.38 | 1.00 | 0.81 | 0.87 | 0.81 |
Debt / equity (x) | 0.41 | 0.54 | 0.57 | 0.56 | 0.59 |
Net debt / EBITDA, S&P basis (x) | 2.86 | 34.43 | 6.21 | 5.31 | 4.17 |
Interest coverage, OP ÷ cash interest (x) | 6.5 | -3.2 | 0.9 | 1.7 | 2.8 |
Asset turnover (x) | 0.71 | 0.66 | 0.62 | 0.65 | 0.61 |
Cash conversion cycle, year-end basis (days) | 120 | 142 | 150 | 175 | 173 |
Revenue History
| Quarter (KRW Bn) | Revenue | YoY | Operating income | YoY | Net income |
|---|---|---|---|---|---|
Q1 2025 | 246.6 | -1.4% | 11.9 | -5.0% | 7.8 |
Q2 2025 | 242.2 | -2.5% | 16.5 | +92.7% | 11.4 |
Q3 2025 | 234.2 | +0.8% | 18.1 | +142.4% | 20.0 |
Q4 2025 (derived) | 236.0 | — | 11.8 | — | — |
Q1 2026 | 240.3 | -2.6% | 19.3 | +62.0% | 17.9 |
Q2 2026 | 251.2 | +3.7% | 6.6 | -59.8% | 17.6 |
Segment Overview — CKD Healthcare
| Segment | Domestic vs. export exposure (qualitative) | Evidence |
|---|---|---|
CKD Healthcare | Predominantly domestic. Exported Lacto-Fit to China via cross-border channels in 2019–2020. | Daishin Securities (April 2020) noted Lacto-Fit export expansion to China. Current export share not disclosed. |
Kyongbo Pharm | Mixed. API exports plus domestic API and finished-dose sales. ADC CDMO targets global clients. | API business described as facing Chinese and Indian competition. ADC CDMO strategy aims at the global market (Bizwatch, June 2025). |
CKD Bio | Significant export exposure in APIs (immunosuppressants, antibiotics). Toxin to target China, the US, the Middle East and Southeast Asia. | NICE D&B and KIRS reports; China Phase 3 and US IND for Tyemvers |
CKD Industry & others | Domestic | Real-estate and services affiliates |
Share Price and Market Valuation
| Price metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price, adjusted (KRW) | 68,842 | 48,900 | 55,936 | 46,360 | 44,951 |
Year-end market cap (KRW Bn) | 379.3 | 258.2 | 282.6 | 227.1 | 220.2 |
Return window
| Return window | Return | Basis |
|---|---|---|
Latest price | KRW 37,350 (6 October 2026) | S&P Global |
1-year | About −17% to −21% | S&P Global (August 2026); Paasa |
3-year | About −33% | vs. FY2023 year-end adjusted close (computed) |
5-year | About −55% | Paasa |
52-week range | KRW 36,000–55,600 (as of August 2026) | S&P Global |
Beta | 0.53 | S&P Global |
Valuation Multiples
| Multiple | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
P/E (x) | 23.72 | 240.33 | 6.01 | 6.76 | 5.45 |
P/B (x) | 0.45 | 0.32 | 0.34 | 0.27 | 0.24 |
EV/EBITDA (x) | 12.38 | 82.08 | 15.07 | 11.53 | 9.22 |
EV/Sales (x) | 0.94 | 0.91 | 1.07 | 0.95 | 0.98 |
Dividend yield (%) | 2.03 | 2.86 | 2.50 | 3.02 | 3.11 |
Valuation Snapshot
| Multiple | Value |
|---|---|
P/E | 3.42x |
P/B | 0.19x |
EV/EBITDA | 9.00x |
EV/Sales | 0.94x |
Dividend yield | 3.75% |
Enterprise value | About KRW 904 bn (includes minority interests and net debt) |
Credit Ratings
| Agency | Rating | Outlook |
|---|---|---|
Domestic (Korea) | A+ (corporate bond, per Dealsite, June 2026; Korea Ratings analyst commentary cited) | Not specifically confirmed |
Moody's / S&P / Fitch | Not rated | — |
Capital Instruments
| Instrument | Amount (KRW Bn) | Maturity |
|---|---|---|
Short-term borrowings (FY2025) | 389.6 | Within 1 year (rolling bank lines) |
Current portion of long-term debt (FY2025) | 90.7 | Within 1 year; includes the bond refinanced in July 2026 (about KRW 32 bn) |
Bond 4-1 | 32.0 | About July 2028 (2-year) |
Bond 4-2 | 45.0 | About July 2029 (3-year) |
Long-term debt, other (FY2025) | 55.8 | — |
Use Details
| Use | Amount |
|---|---|
Refinancing | KRW 32 bn |
Operating funds (SG&A, taxes, dividends) | KRW 15 bn |
Subsidiary stake purchases and new investments | KRW 30 bn |
Analyst Conclusions
Guidance and Expectations
CKD Holdings: No formal consolidated guidance. Only one broker covers the stock, so consensus growth forecasts are not meaningful.
Chong Kun Dang (associate): A May 2026 broker report forecasts associate operating income of about KRW 80 bn in 2026 and about KRW 78 bn in 2027 (separate basis). That implies flat equity-method income.
Credit view: Korea Ratings expects good earnings capacity centred on Chong Kun Dang and CKD Healthcare's margin recovery, with rising leverage from Baegot capex.
Bull Case
-
Sum-of-the-parts dislocation. At its May 2026 market value of about KRW 1.1 tn, the 26.70% Chong Kun Dang stake is worth about KRW 295 bn. Add 43.41% of Kyongbo, about 39% of CKD Bio and 51% of CKD Healthcare (FY2025 operating income KRW 32.3 bn). Gross asset value comfortably exceeds the market cap of about KRW 180 bn, even after holding-level net debt.
-
Durable earnings inflection at CKD Healthcare. H1 2026 operating income rose 54% to KRW 22.2 bn at a 9.8% margin, and the subsidiary targets double-digit margins by 2027. Consolidated operating income has risen from KRW −32.9 bn to KRW 58.3 bn in three years.
-
Multiple optionality catalysts. Tyemvers China filing after positive Phase 3; Kyongbo ADC plant start-up; CKD-510 Phase 2 readout (2027) feeding associate value.
Bear Case
-
Structural discount may be permanent. Succession is being executed through subsidiary-stake gifts, and media speculate on share swaps. Minority holders could see value transferred rather than unlocked. ROE of about 6% does not justify a re-rating on its own.
-
Leverage and cash conversion. Net debt is about 4.2x EBITDA, short-term funding dominates, free cash flow is marginal (KRW 20.1 bn in FY2025), and ADC capex is rising. Associate Baegot spending may constrain dividends up the chain.
-
Subsidiary execution risk. Kyongbo's licence loss and margin compression (Q2 2026 operating income KRW 0.9 bn). CKD Bio's recurring losses. Supplements market contraction. Q2 2026 consolidated operating income fell 60%.
Catalysts and Monitorables (Next 12 Months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Mid-November 2026 | Q3 2026 results: test whether the Q2 profit dip was transitory |
| Late 2026 – 2027 | Kyongbo appeal and stay outcome on the 23 products |
| 2,027 | Tyemvers China approval timeline; US Phase 1 progress |
| 2026–2027 | Kyongbo ADC plant commissioning, GMP certification and first client contracts |
| 2026–2027 | CKD Healthcare top-line stabilisation after the H1 2026 decline of 8.9% |
| Ongoing | Further owner-family transactions at the holding-company level; any in-kind contribution or tender |
| Ongoing | Chong Kun Dang: Wegovy run-rate, CKD-510 Phase 2 progress, CKD-703 data, Baegot capex pacing |
| March 2027 | FY2026 dividend decision (watch whether DPS rises above KRW 1,400) |
| Ongoing | Holding-company stake purchases (about KRW 10 bn a year) and use of bond proceeds |
Analyst Verdict
CKD Holdings is a classic Korean family holding company. Reported earnings understate the underlying assets, and governance and leverage explain much of the discount.
On fundamentals, the past three years show real operational progress. Consolidated operating income rose from a KRW 32.9 bn loss in FY2022 to a KRW 58.3 bn profit in FY2025, driven mainly by CKD Healthcare's cost discipline. The shares trade at about 3–4x earnings and about 0.2–0.3x book. That is cheap even by Korean holding-company standards, and cheaper than Dong-A Socio or GC Holdings on price-to-book.
Three things temper the case. First, top-line growth has been close to zero for five years. The consolidated subsidiaries operate in contested markets: promotion-heavy supplements, commoditised APIs and a crowded toxin field. Second, the balance sheet carries about KRW 424 bn of net debt, mostly short-term, and free cash flow has been thin. Kyongbo's ADC build-out and the associate's KRW 2.2 tn Baegot campus will absorb cash for years. Third, the controlling family is moving through succession using subsidiary stakes. The chairman retains 33.73% of the holding company, so outside shareholders face uncertainty about how that last step will be executed and priced.
The Q2 2026 profit drop shows earnings remain fragile. So does the Kyongbo licence ruling. Neither is a balance-sheet threat at holding-company level.
On balance, the stock looks fundamentally undervalued on a sum-of-the-parts basis, but the catalysts to close that gap are largely outside minority shareholders' control. Investors should treat it as a value position with a long holding period, sized for governance risk. The key signposts are:
-
Sustained double-digit margins at CKD Healthcare.
-
Tangible ADC contracts at Kyongbo.
-
China approval for Tyemvers.
-
A transparent, minority-friendly succession structure.
-
Any step-up in shareholder returns beyond the static KRW 1,400 dividend.
Absent progress on items 4 and 5, the discount is likely to persist even as operating results improve.
Principal Sources
| Category | Sources |
|---|---|
| Company | CKD Holdings corporate website (company overview, affiliate list) |
| Financial data | S&P Global Market Intelligence via StockAnalysis (income statement, balance sheet, cash flow, ratios; data to Q2 2026); Butler (DART summaries, segment mix); ETFShopping (quarterly DART results, ownership); Paasa; Craft; Simply Wall St; ROIC.ai |
| AGM disclosures | Medifonews and Dailypharm (26 March 2026; 28 March 2024) |
| Credit and bonds | Dealsite (24 June 2026), Dailypharm (26 June 2026), SBS Biz (26 June 2026), Korea Financial News (19 June 2026) |
| Ownership and succession | Dailypharm (29 August 2026; 7 August 2025; 7 January 2025), Medical Times (10 October 2026), The Fact (31 August 2026), Dealsite (9 September 2025), HuffPost Korea / C-Journal (2026) |
| Subsidiaries | Dailypharm (CKD Healthcare: 23 March 2026, 8 September 2026, 21 November 2025, 25 March 2025; Kyongbo: 24 January 2025, 28 August 2026; CKD Bio toxin: 1 April 2025), Dealsite (12 June 2025), MoneyToday (6 November 2025), Bizwatch (24 June 2025), MTN (27 March 2025; 20 May 2026), Asia Economy (20 January 2026), Digital Today (16 September 2025), Toyo Economy (14 July 2025) |
| Chong Kun Dang (associate) | Dealsite (2 February 2026; 31 July 2026), Bizwatch (2 February 2026), Dailypharm (20 March 2026), CEO Score Daily (12 June 2026), Insight (13 July 2026), Toyo Economy (12 July 2026; 14 September 2026), Medifonews (18 September 2025), broker reports (Eugene, Kiwoom, May 2026 broker note) |
| Peers | Dealsite (Dong-A Socio, 9 February 2026), Butler (GC Holdings), AlphaDistill (Huons Global, GC Holdings), Meritz (Hanmi Pharm) |
| Market data | Korea Health Functional Food Association via fnnews, Metro and MTN; IMARC Group; IQVIA via Bizwatch |
| History | Dailypharm (11 April 2011), Kormedi (7 February 2023), Medical Times (7 February 2013), Insight |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background |
|---|---|---|---|
Lee Jang-han (이장한), age 74 | Chairman; controlling shareholder (33.73%) | Group chairman since the 1990s, after the founder's death in 1993 | Son of founder Lee Jong-geun. |
Choi Hee-nam (최희남), age about 66 | CEO / Representative Director, inside director | Since 28 March 2024 | BA and MA in Economics (Hanyang University); PhD in Economics (University of Pittsburgh). IMF Executive Director (2016); CEO of Korea Investment Corporation (2018); Chairman of the Board of SC First Bank (from 2022); Milken Institute Global Fellow. Compensation not disclosed individually. |
Lee Hee-jae (이희재), age about 55 | Inside director (M&A / investment) | Since 28 March 2024 | EMBA (Kellogg–HKUST). Goldman Sachs, Deutsche Bank, J.P. Morgan (MD, M&A advisory), Yulchon law firm (M&A adviser), CJ Corp. EVP and head of M&A (from 2020). |
Na Seung-yong (나승용) | Outside director | Re-elected 26 March 2026 | Former President, Mirae Asset Global Investments |
Jo Jeong-hee (조정희) | Outside director | Re-elected 26 March 2026 | Managing partner, D'Code law firm |
Jo Jung-yong (조중용) | Standing auditor | Re-elected 28 March 2024 | Full-time statutory auditor |
Governance Detail
| Company | CEO | Since | Background |
|---|---|---|---|
Chong Kun Dang (associate) | Kim Young-joo, President and CEO | 2015; re-elected March 2024 | Also chairs the Chong Kun Dang board |
CKD Bio | Park Wan-gap | March 2024 | Hanyang University chemistry (BSc, MSc). Joined Kyongbo in 2010; API sales head from 2022. |
Kyongbo Pharm | Kim Tae-young, President | — | Former CKD Holdings CEO |
CKD Healthcare | Jung Soo-chul | May 2025 | First leadership change in 14 years |
Archela (Chong Kun Dang subsidiary) | Dr Lee Ju-hee | October 2025 | Seoul National University PhD; MSKCC postdoc; ex-Chong Kun Dang research |
Board & Management Changes
| Date | Change |
|---|---|
28 March 2024 | Choi Hee-nam appointed CEO; Lee Hee-jae added to the board; Kim Tae-young not re-nominated. |
May 2025 | Jung Soo-chul appointed CEO of CKD Healthcare. |
26 March 2026 | Outside directors Na Seung-yong and Jo Jeong-hee re-elected. At Chong Kun Dang, Lee Kyu-woong re-elected and Kwon Yu-kyung newly elected as inside directors; Lee Woo-ram (ex-Samil PwC) appointed standing auditor. |
Major Shareholders
| Holder | Stake in CKD Holdings | Source / date |
|---|---|---|
Lee Jang-han | 33.73% | Dailypharm, August 2026 |
Largest shareholder plus related parties (total) | 48.09% | Change-in-holdings report, 8 June 2026. This was 46.02% in November 2021 and 45.98% in early 2021. |
Bell SM (family-controlled affiliate) | 12,569 shares (about 0.25%) at April 2025; buying continued into 2025 | Dailypharm, August 2025 |
Treasury shares | About 0.25m shares (about 5% of issued); KRW 16.3 bn at cost | S&P Global balance sheet |
5%-holder report filed 30 September 2026 | Filer not identified in sources reviewed | DART filing list (Butler) |
Competitive Landscape
Peer Comparison FY2025
| Peer | FY2025 revenue (KRW Bn) | FY2025 OP margin | Notes |
|---|---|---|---|
GC Holdings (005250) | 2,451.5 | 1.5% | Net loss in FY2025. P/B about 0.54–0.77x. |
Dong-A Socio Holdings (000640) | 1,429.8 | 6.8% | Revenue +7.2%. Announced absorption of Dong-A Pharm. P/B about 0.5x. |
Huons Global (084110) | 847.5 | 10.7% | Revenue +4.2% |
Peer Comparison FY2025 — Revenue
| Metric (FY2025) | CKD Holdings | Dong-A Socio Holdings | GC Holdings | Huons Global |
|---|---|---|---|---|
Revenue (KRW Bn) | 959.0 | 1,429.8 | 2,451.5 | 847.5 |
Revenue growth YoY (%) | 0.1 | 7.2 | 11.2 | 4.2 |
Operating margin (%) | 6.1 | 6.8 | 1.5 | 10.7 |
R&D intensity (% of revenue) | 2.8 | — | — | — |
P/B (x, latest available) | 0.19 | 0.50 | 0.54 | — |



